Evaluation of anti-m?llerian hormone levels as a predictive factor of response to weight loss treatment in obese infertile women with PCOS.

Royan institute0 个研究点目标入组 80 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•1-Diagnosis of PCOS, according to the Rotterdam Consensus Workshop Group, by 2 of the following 3 criteria:
•Menstrual irregularity (cycle length<26 d or >31 d or variation between consecutive cycles of >3 d);
•Clinical (hirsutism assessed by a Ferriman-Gallwey score > 8) or biochemical [free androgen index (FAI) > 5.4 or testosterone_1.4 nmol/L] hyperandrogenism;
•Positive ultrasound presentation of polycystic ovaries by transvaginal scan (More than 12 follicles 9-2 mm and increased ovarian volume greater than 10 cm3) .
•2-Age between 18 -40 years old.
•Exclusion criteria:
•1.Body mass index (BMI; in kg/m2) < 30.
•2.Type 2 diabetes mellitus.
•3. Related endocrine disorders [identified by assessment of thyroid-stimulating hormone (TSH), prolactin, and 17_hydroxyprogesterone].
•4.The use of medications affecting the hypothalamus - pituitary - ovarian axis and insulin-sensitizing agents (metformin) is not permitted during the study phase and 12 wk before commencement of the study phase. Also, the use of oral contraceptives is not permitted during and 4 wk before commencement of the study phase.
•5.Cases of alcoholism and smoking.
•6.Regular exercise activities during the study.

发起方